1. Home
  2. PRAX
  3. PRAX News

Latest Praxis Precision Medicines Inc. (PRAX) News on February 23, 2025

PRAX

MT Newswires

12 days ago

Deutsche Bank Initiates Coverage on Praxis Precision Medicines With Buy Rating, $111 Price Target

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

18 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Present at Two February Investor Conferences
PRAX

GlobeNewswire

19 days ago

Praxis Precision Medicines to Present at Two February Investor Conferences

PRAX

MT Newswires

a month ago

Truist Securities Adjusts Price Target on Praxis Precision Medicines to $175 From $150, Keeps Buy Rating

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
PRAX

GlobeNewswire

a month ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
PRAX

GlobeNewswire

2 months ago

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

PRAX

MT Newswires

2 months ago

Praxis Precision Medicines Files for Mixed Shelf, $250 Million Common Stock Sale

PRAX

MT Newswires

2 months ago

Praxis Says FDA Grants Rare Pediatric Disease Designation to Relutrigine to Treat Dravet Syndrome

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
PRAX

GlobeNewswire

2 months ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Praxis Precision Medicines to Present at Upcoming December Investor Conferences
PRAX

GlobeNewswire

3 months ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
PRAX

GlobeNewswire

3 months ago

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
PRAX

Simply Wall St.

3 months ago

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...
PRAX

GuruFocus.com

4 months ago

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
PRAX

GlobeNewswire

4 months ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

PRAX

MT Newswires

4 months ago

Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating

PRAX

MT Newswires

4 months ago

Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
PRAX

Zacks

4 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PRAX

GlobeNewswire

4 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
PRAX

GlobeNewswire

4 months ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
PRAX

Simply Wall St.

4 months ago

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Health Care Roundup: Market Talk
PRAX

The Wall Street Journal

4 months ago

Health Care Roundup: Market Talk

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals
PRAX

Insider Monkey

4 months ago

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
PRAX

Zacks

5 months ago

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
PRAX

GlobeNewswire

5 months ago

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

PRAX

GuruFocus.com

5 months ago

Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc

Praxis Precision Medicines to Participate in Upcoming Investor Conferences
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
PRAX

Zacks

6 months ago

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

PRAX

MT Newswires

6 months ago

Wedbush Adjusts Price Target on Praxis Precision Medicines to $51 From $48, Maintains Neutral Rating

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
PRAX

Benzinga

6 months ago

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
PRAX

Zacks

6 months ago

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
PRAX

Zacks

6 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
PRAX

Zacks

7 months ago

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

PRAX

MT Newswires

7 months ago

Oppenheimer Starts Praxis Precision Medicines With Outperform Rating, $134 Price Target

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
PRAX

Zacks

7 months ago

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

PRAX

MT Newswires

8 months ago

Needham Initiates Praxis Precision Medicines at Buy With $145 Price Target

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
PRAX

Zacks

8 months ago

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure
PRAX

Investor's Business Daily

8 months ago

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate
PRAX

Simply Wall St.

9 months ago

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate

Praxis Precision Medicines to Participate in Upcoming Investor Conferences
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
PRAX

Simply Wall St.

9 months ago

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

10 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
PRAX

Zacks

10 months ago

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?

PRAX

MT Newswires

10 months ago

Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
PRAX

GlobeNewswire

10 months ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
PRAX

Zacks

10 months ago

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why

Praxis Precision Medicines to Participate in Upcoming April Conferences
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care Roundup: Market Talk
PRAX

The Wall Street Journal

a year ago

Health Care Roundup: Market Talk

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
PRAX

Zacks

a year ago

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis (PRAX) Surges on Positive Epilepsy Study Results
PRAX

Zacks

a year ago

Praxis (PRAX) Surges on Positive Epilepsy Study Results

Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High
PRAX

Investor's Business Daily

a year ago

Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High

Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big
PRAX

Investor's Business Daily

a year ago

Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Praxis Precision Medicines to Host PRAX-628 Program Update
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Host PRAX-628 Program Update

A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
PRAX

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
PRAX

Zacks

a year ago

What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?

Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates
PRAX

GuruFocus.com

a year ago

Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates

Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
PRAX

Zacks

a year ago

Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
PRAX

Zacks

a year ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is definitely on the radar of institutional investors who own 47% of the company
PRAX

Simply Wall St.

a year ago

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is definitely on the radar of institutional investors who own 47% of the company

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Chuck Royce Adjusts Position in International General Insurance Holdings Ltd
PRAX

GuruFocus.com

a year ago

Chuck Royce Adjusts Position in International General Insurance Holdings Ltd

Is Anywhere Real Estate (HOUS) a Solid Growth Stock? 3 Reasons to Think "Yes"
PRAX

Zacks

a year ago

Is Anywhere Real Estate (HOUS) a Solid Growth Stock? 3 Reasons to Think "Yes"

Coastal Financial Corporation Announces Fourth Quarter and Fiscal Year 2023 Results
PRAX

GlobeNewswire

a year ago

Coastal Financial Corporation Announces Fourth Quarter and Fiscal Year 2023 Results

Leading UK Fashion Brand White Stuff Boosts Customer Experience with New Composable Website on BigCommerce
PRAX

Business Wire

a year ago

Leading UK Fashion Brand White Stuff Boosts Customer Experience with New Composable Website on BigCommerce

Chipotle’s Gen Z Hiring Strategy: More Than Just Money
PRAX

Barrons.com

a year ago

Chipotle’s Gen Z Hiring Strategy: More Than Just Money

Are Robust Financials Driving The Recent Rally In Precision Drilling Corporation's (TSE:PD) Stock?
PRAX

Simply Wall St.

a year ago

Are Robust Financials Driving The Recent Rally In Precision Drilling Corporation's (TSE:PD) Stock?

Alerus (ALRS) Misses Q4 Earnings Estimates
PRAX

Zacks

a year ago

Alerus (ALRS) Misses Q4 Earnings Estimates

Where Will Nikola Stock Be in 5 Years?
PRAX

Motley Fool

a year ago

Where Will Nikola Stock Be in 5 Years?

Amprius Achieves Globally Recognized Aerospace & Defense AS9100 Certification
PRAX

Business Wire

a year ago

Amprius Achieves Globally Recognized Aerospace & Defense AS9100 Certification

PRAX

GlobeNewswire

a year ago

Ragnarok Idle Adventure Ranked Top on Both Markets after its Launching in Thailand!

Beal Bank Provides $637.5 million of $885.0 million in New Debt to ProFrac Holding Corp (NASDAQ: ACDC) and its Subsidiaries
PRAX

PR Newswire

a year ago

Beal Bank Provides $637.5 million of $885.0 million in New Debt to ProFrac Holding Corp (NASDAQ: ACDC) and its Subsidiaries

Recent Price Trend in Pangaea Logistics (PANL) is Your Friend, Here's Why
PRAX

Zacks

a year ago

Recent Price Trend in Pangaea Logistics (PANL) is Your Friend, Here's Why

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
PRAX

GlobeNewswire

a year ago

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks
PRAX

StockStory

a year ago

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks
PRAX

StockStory

a year ago

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks

Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
PRAX

Zacks

a year ago

Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron

Estimating The Intrinsic Value Of Accel Entertainment, Inc. (NYSE:ACEL)
PRAX

Simply Wall St.

a year ago

Estimating The Intrinsic Value Of Accel Entertainment, Inc. (NYSE:ACEL)

7 Undervalued Stocks to Buy for the Contrarian Investor
PRAX

InvestorPlace

a year ago

7 Undervalued Stocks to Buy for the Contrarian Investor

Q3 Rundown: WalkMe (NASDAQ:WKME) Vs Other Sales And Marketing Software Stocks
PRAX

StockStory

a year ago

Q3 Rundown: WalkMe (NASDAQ:WKME) Vs Other Sales And Marketing Software Stocks

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Great Wall Motor Selects Cerence to Power In-Car Experience as Automaker Expands Globally
PRAX

GlobeNewswire

a year ago

Great Wall Motor Selects Cerence to Power In-Car Experience as Automaker Expands Globally

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
PRAX

PR Newswire

a year ago

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
PRAX

GlobeNewswire

a year ago

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
PRAX

Zacks

a year ago

Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?

Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)
PRAX

Zacks

a year ago

Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)

Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know
PRAX

Zacks

a year ago

Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know

ArcelorMittal (MT) Rejects Italy Government's Stake Plan in ADI
PRAX

Zacks

a year ago

ArcelorMittal (MT) Rejects Italy Government's Stake Plan in ADI

Share on Social Networks: